Drug Trial Radar · NCT06172309
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Sep 24, 2021
Primary completion
Apr 20, 2024
Study completion May 27, 2024
Sponsor
- Lead sponsor
- Nanjing Chia-tai Tianqing PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic effect of NTQ1062 in patients with advanced solid tumors. The study comprises a dose-escalation phase and a dose-expansion phase. 1. Dose-escalation:using 3+3 design to evaluate the safety, tolerability, and pharmacokinetic profile of NTQ1062 at 20, 50, 100, 200, 300, 400 mg in patients with advanced solid tumors, and to determine the maximum tolerated dose (MTD). 2. Dose-expansion:the dose-expansion study will evaluate the safety, tolerability, and preliminary pharmacodynamic effect of the MTD for NTQ1062 in patients with advanced solid tumors, and to identify the recommended phase 2 dose (RP2D).
Conditions
- Advanced Solid Tumors
Interventions
NTQ1062Drug
tablet(s) PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: First treatment cycle (i.e., the first 28 days post the first dose)
- Recommended phase 2 dose (RP2D)Time frame: First treatment cycle (i.e., the first 28 days post the first dose)
- Adverse eventsTime frame: through study completion, an average of 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shandong Cancer Hospital
Jinan, Shandong, China
Shanghai East hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.